Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Gains from Sales and Divestitures (2021 - 2026)

Climb Bio filings provide 6 years of Gains from Sales and Divestitures readings, the most recent being $563.0 for Q1 2026.

  • Quarterly Gains from Sales and Divestitures fell 99.86% to $563.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $563.0 through Mar 2026, down 99.86% year-over-year, with the annual reading at $929563.0 for FY2025, 131.52% up from the prior year.
  • Gains from Sales and Divestitures hit $563.0 in Q1 2026 for Climb Bio, down from $929563.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $929563.0 in Q4 2025 and bottomed at $563.0 in Q1 2026.
  • Average Gains from Sales and Divestitures over 5 years is $274514.1, with a median of $124737.0 recorded in 2023.
  • The largest annual shift saw Gains from Sales and Divestitures soared 1533.51% in 2025 before it tumbled 99.86% in 2026.
  • Climb Bio's Gains from Sales and Divestitures stood at $154869.0 in 2022, then decreased by 19.46% to $124737.0 in 2023, then soared by 221.88% to $401500.0 in 2024, then soared by 131.52% to $929563.0 in 2025, then crashed by 99.94% to $563.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Gains from Sales and Divestitures are $563.0 (Q1 2026), $929563.0 (Q4 2025), and $929001.0 (Q3 2025).